Known targets — ChEMBL curated mechanism
rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Linezolid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 12/20 | 0.98 |
| ▸ | MAOA | P21397 | 7/20 | 0.98 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.98 |
| ▸ | SDHA | P31040 | 2/20 | 0.98 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | CALML3 | P27482 | 1/20 | 0.98 |
| ▸ | F10 | P00742 | 4/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Linezolid SCHEMBL2277149 | 1.00 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL1561095 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30226927 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2222512 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5524444 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL30638355 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL374752 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL5027 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL7992562 | 0.99 | MAOB (1.00) | MAOBMAOAPTGS1SDHALMNA | |
| Linezolid SCHEMBL2279924 | 0.98 | MAOB (0.98) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170066728-A1 | PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | JUBILANT LIFE SCIENCES LTD (IN) | 2017-03-09 | — | — | US | claimed |
| EP-2852580-A1 | IMPROVED PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | Jubilant Life Sciences Ltd. (IN) | 2015-04-01 | — | — | EP | claimed |
| US-20150025236-A1 | PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | JUBILANT LIFE SCIENCES LTD (IN) | 2015-01-22 | — | — | US | claimed |
| WO-2013111048-A1 | IMPROVED PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | JUBILANT LIFE SCIENCES LIMITED (IN) | 2013-08-01 | — | — | WO | claimed |
| US-20090093631-A1 | Processes for the preparation of a linezolid intermediate, linezolid hydroxide | TEVA PHARMACEUTICALS USA, INC. | 2009-04-09 | — | — | US | claimed |
| WO-2009032294-A2 | PROCESSES FOR THE PREPARATION OF A LINEZOLID INTERMEDIATE, LINEZOLID HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | WO | claimed |
| EP-1745028-A2 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-24 | — | — | EP | claimed |
| WO-2006110155-A1 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-10-19 | — | — | WO | claimed |
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2006-05-25 | — | — | US | claimed |
| US-20170066728-A1 | PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | JUBILANT LIFE SCIENCES LTD (IN) | 2017-03-09 | — | — | US | disclosed |
| US-20170066728-A1 | PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | JUBILANT LIFE SCIENCES LTD (IN) | 2017-03-09 | — | — | US | disclosed |
| WO-2015068121-A1 | PROCESS FOR PREPARATION OF CRYSTALLINE FORM I OF LINEZOLID AND ITS COMPOSITIONS | UNIMARK REMEDIES LTD. (IN) | 2015-05-14 | — | — | WO | disclosed |
| EP-2852580-A1 | IMPROVED PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | Jubilant Life Sciences Ltd. (IN) | 2015-04-01 | — | — | EP | disclosed |
| EP-2852580-A1 | IMPROVED PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | Jubilant Life Sciences Ltd. (IN) | 2015-04-01 | — | — | EP | disclosed |
| WO-2009032294-A2 | PROCESSES FOR THE PREPARATION OF A LINEZOLID INTERMEDIATE, LINEZOLID HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032294-A2 | PROCESSES FOR THE PREPARATION OF A LINEZOLID INTERMEDIATE, LINEZOLID HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032294-A2 | PROCESSES FOR THE PREPARATION OF A LINEZOLID INTERMEDIATE, LINEZOLID HYDROXIDE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2009-03-12 | — | — | WO | disclosed |
| EP-1745028-A2 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | Teva Pharmaceutical Industries Ltd (IL) | 2007-01-24 | — | — | EP | disclosed |
| WO-2006110155-A1 | SOLID FORMS OF LINEZOLID AND PROCESSES FOR PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD (IL) | 2006-10-19 | — | — | WO | disclosed |
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093631-A1 | Processes for the preparation of a linezolid intermediate, linezolid hydroxide | SORD, SI, KHK | MAOB 2417/4885MAOA 1545/4885PTGS1 2668/4885 |
| US-20170066728-A1 | PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | CYP2C9, CYP2F1, CYP2C19 | MAOB 2150/4885MAOA 1712/4885PTGS1 1591/4885 |
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | F9, Q6ZSR9, TBCD | MAOB 2551/4885MAOA 1756/4885PTGS1 4164/4885 |
| US-20150025236-A1 | PROCESS FOR THE PREPARATION OF STABLE CRYSTALLINE FORM-I OF LINEZOLID, SUBSTANTIALLY FREE OF RESIDUAL SOLVENT | CYP2C9, CYP2C19, CYP2F1 | MAOB 1808/4885MAOA 1539/4885PTGS1 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.